Skip to content
DataLookout
Menu

NCT02653118

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 7 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 2 words
    • Trial sites expanded: 0 → 13 locations
    • Publications: details revised at 2 of 2 entries
  2. Notable Eligibility criteria shortened, about 12 words
    • Publications: details revised at 1 of 2 entries
    v16
  3. Notable Primary and study completion dates: Jan 1, 2024 to Jan 1, 2040
    • Primary endpoint revised
    v15
  4. Minor Publications: 1 to 2v13
  5. Minor Primary and study completion dates: Jan 2024 to Jan 1, 2024
    • Start date: Jan 2016 to Jan 22, 2016
    v9
  6. Minor Trial status: Not Yet Recruiting to Active, Not Recruitingv2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Combined Incidence of HPV Type 16, 18, 31, 33, 45, 52, or 58-related Cervical Intraepithelial Neoplasia (CIN) Grades 2 or 3, Adenocarcinoma In Situ (AIS), and Cervical Cancer in Cohort 1
Timeframe: Up to 30 years after vaccination in V503-001 base study

Arms and interventions

Cohort 1: V503 in the Base Study

Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.

Cohort 2: GARDASIL in the Base Study

Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.

Biologicals: V503, GARDASIL

Sites

13 sites in 3 countries

Norway 6, Denmark 5, Sweden 2